Successful completion of Engineering Validation Testing: Nuheara Ltd.’s (ASX: NUH) stock rose 2% on June 27, 2018 after the company completed the Engineering Validation Testing (EVT) for the company’s third product, LiveIQ after the successful release of IQbuds & IQbuds BOOST. This is an important milestone in preparation for LiveIQ’s mass production. LiveIQ is the world’s first hybrid Active Noise Cancellation hearing bud and expected to deliver a new level of sophistication, intelligence, affordability and street appeal, to a much broader lifestyle-oriented audience. As per the company, LiveIQ development is on track for shipping to start in the fourth quarter of the 2018 calendar year. This will be well ahead of Apple’s predicted noise cancellation AirPods in Q4 2019. NUH is encouraged by the recent news that Apple will be venturing into noise cancellation AirPods. Apple has 19% of the international smartphone market, but NUH has the ability to service all smartphones: Android and IOS, which will provide NUH a strong global opportunity to leverage the rising awareness of hearables devices, which Apple’s new product will also help to generate. Moreover, LiveIQ is expected to open up a broader consumer market for NUH without compromising the level of intelligence. NUH has successfully completed the build of 50 sets of LiveIQ in order to validate the engineering design. Additionally, after the completion of the EVT stage, NUH is now in a position to make improvements to the design that will include fine tuning of the tooling and update circuit board design in preparation for the DVT stage in the coming weeks. DVT is expected to be manufactured with a much larger sample set with the aim of also completing reliability testing and certification testing. Meanwhile, NUH stock has fallen 11.82% in three months as on June 26, 2018.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.